Thomas M. Caparrotta

1.4k total citations
23 papers, 583 citations indexed

About

Thomas M. Caparrotta is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Thomas M. Caparrotta has authored 23 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Thomas M. Caparrotta's work include Diabetes Management and Research (11 papers), Diabetes Treatment and Management (9 papers) and Diabetes and associated disorders (4 papers). Thomas M. Caparrotta is often cited by papers focused on Diabetes Management and Research (11 papers), Diabetes Treatment and Management (9 papers) and Diabetes and associated disorders (4 papers). Thomas M. Caparrotta collaborates with scholars based in United Kingdom, Canada and United States. Thomas M. Caparrotta's co-authors include James W. Dear, Helen M. Colhoun, Marc Evans, James Coulson, John Paul Thompson, Daniel J. Antoine, Paul McKeigue, Sarah H. Wild, Stuart J. McGurnaghan and Luke A. K. Blackbourn and has published in prestigious journals such as Circulation, PLoS ONE and Diabetes Care.

In The Last Decade

Thomas M. Caparrotta

23 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas M. Caparrotta United Kingdom	16	231	153	110	95	77	23	583
Elizabeth Landrum Michalets United States	10	60 0.3×	249 1.6×	115 1.0×	119 1.3×	31 0.4×	16	808
Rakesh Gupta India	15	237 1.0×	47 0.3×	65 0.6×	135 1.4×	34 0.4×	80	983
C. Kreft-Jaïs France	14	211 0.9×	70 0.5×	67 0.6×	138 1.5×	27 0.4×	38	774
P. Taboulet France	17	115 0.5×	90 0.6×	117 1.1×	96 1.0×	123 1.6×	57	997
Srikanth C. Nallani United States	11	55 0.2×	279 1.8×	88 0.8×	26 0.3×	77 1.0×	17	877
Elizabeth Farrington United States	15	51 0.2×	141 0.9×	61 0.6×	157 1.7×	24 0.3×	46	1.1k
Kathryn M. Momary United States	14	179 0.8×	374 2.4×	72 0.7×	87 0.9×	51 0.7×	39	746
Larry K. Golightly United States	16	190 0.8×	33 0.2×	107 1.0×	135 1.4×	25 0.3×	31	643
Hieronymus J. Derijks Netherlands	14	173 0.7×	28 0.2×	97 0.9×	82 0.9×	23 0.3×	47	699
Joseph P. Kitzmiller United States	14	57 0.2×	175 1.1×	79 0.7×	171 1.8×	30 0.4×	31	714

Countries citing papers authored by Thomas M. Caparrotta

Since Specialization

Citations

This map shows the geographic impact of Thomas M. Caparrotta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Caparrotta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Caparrotta more than expected).

Fields of papers citing papers by Thomas M. Caparrotta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas M. Caparrotta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Caparrotta. The network helps show where Thomas M. Caparrotta may publish in the future.

Co-authorship network of co-authors of Thomas M. Caparrotta

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas M. Caparrotta. A scholar is included among the top collaborators of Thomas M. Caparrotta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas M. Caparrotta. Thomas M. Caparrotta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGurnaghan, Stuart J., Paul McKeigue, Luke A. K. Blackbourn, et al.. (2024). Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland. Diabetes Care. 47(8). 1342–1349. 3 indexed citations

McCallum, Linsay, Stefanie Lip, Alex McConnachie, et al.. (2024). UMOD Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide. Hypertension. 81(10). 2049–2059. 10 indexed citations

Caparrotta, Thomas M., Emma Carduff, & James W. Dear. (2023). Paracetamol use in adults. BMJ. 383. e070753–e070753. 2 indexed citations

MacIntyre, I., Emma Turtle, Tariq E. Farrah, et al.. (2022). Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial. Circulation. 145(6). 416–423. 30 indexed citations

McGurnaghan, Stuart J., Luke A. K. Blackbourn, Thomas M. Caparrotta, et al.. (2022). Cohort profile: the Scottish Diabetes Research Network national diabetes cohort – a population-based cohort of people with diabetes in Scotland. BMJ Open. 12(10). e063046–e063046. 15 indexed citations

Höhn, Andreas, Stuart J. McGurnaghan, Thomas M. Caparrotta, et al.. (2022). Large socioeconomic gap in period life expectancy and life years spent with complications of diabetes in the Scottish population with type 1 diabetes, 2013–2018. PLoS ONE. 17(8). e0271110–e0271110. 4 indexed citations

McGurnaghan, Stuart J., Paul McKeigue, Stephanie H. Read, et al.. (2021). Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia. 64(9). 2001–2011. 31 indexed citations

Jeyam, Anita, Fraser W. Gibb, John McKnight, et al.. (2021). Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. Diabetologia. 65(1). 159–172. 19 indexed citations

Höhn, Andreas, Anita Jeyam, Thomas M. Caparrotta, et al.. (2021). The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia. 64(6). 1309–1319. 5 indexed citations

10.

O’Reilly, Joseph, Anita Jeyam, Thomas M. Caparrotta, et al.. (2021). Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care. 44(9). 2010–2017. 16 indexed citations

11.

Caparrotta, Thomas M., Robert M. Gifford, Sarah H. Wild, et al.. (2021). Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy. 12(4). 991–1028. 31 indexed citations

12.

Jeyam, Anita, Fraser W. Gibb, John McKnight, et al.. (2021). Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia. 64(6). 1320–1331. 28 indexed citations

13.

McKeigue, Paul, Sharon Kennedy, Amanda Weir, et al.. (2021). Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. BMC Medicine. 19(1). 51–51. 42 indexed citations

14.

Caparrotta, Thomas M., Thomas A. Clay, Sarah H. Wild, et al.. (2021). Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy. 12(4). 969–989. 19 indexed citations

15.

Caparrotta, Thomas M., Luke A. K. Blackbourn, Stuart J. McGurnaghan, et al.. (2020). Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland. Diabetes Care. 43(9). 2034–2041. 14 indexed citations

16.

McKeigue, Paul, Amanda Weir, Jen Bishop, et al.. (2020). Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLoS Medicine. 17(10). e1003374–e1003374. 44 indexed citations

17.

O’Reilly, Joseph, Luke A. K. Blackbourn, Thomas M. Caparrotta, et al.. (2020). Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. Diabetologia. 63(8). 1626–1636. 10 indexed citations

18.

McGurnaghan, Stuart J., Liam Brierley, Thomas M. Caparrotta, et al.. (2019). The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia. 62(4). 621–632. 30 indexed citations

19.

Pettie, Janice, Thomas M. Caparrotta, Robert W. Hunter, et al.. (2019). Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose. EClinicalMedicine. 11. 11–17. 49 indexed citations

20.

Caparrotta, Thomas M., Daniel J. Antoine, & James W. Dear. (2017). Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature. European Journal of Clinical Pharmacology. 74(2). 147–160. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact